Media
Press Releases
May 16, 2024
Lupin Receives Approval from U.S. FDA for Midostaurin Capsules
May 6, 2024
Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP
April 25, 2024
Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
April 23, 2024
Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility
April 22, 2024
Lupin Launches Mirabegron Extended-Release Tablets in the United States
April 12, 2024
U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations
April 9, 2024
Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States
April 8, 2024
Lupin Receives Approval from U.S. FDA for Valbenazine Capsules
April 1, 2024
Lupin Receives Tentative Approval from U.S. FDA for Migalastat Capsules
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.